Skip to content

Bioventus BVS Free cash flow yield

Free cash flow yield at other companies

Stryker logo
StrykerSYK
3.6%+1.1pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-31.5%+23.5pp
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
8.2%+1.8pp
Medtronic logo
MedtronicMDT
5.2%+0.4pp
Artivion logo
ArtivionAORT
-0%-1.1pp
Globus Medical logo
Globus MedicalGMED
5.2%0.0pp

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Calculated from Bioventus’s reported figures.

Based on trailing twelve months.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's free cash flow yield?
Bioventus (BVS) reported free cash flow yield of 16.4% in Q1 2026.
How has Bioventus's free cash flow yield changed year-over-year?
Bioventus's free cash flow yield increased by 313.9% year-over-year, from 4% to 16.4%.
What is the long-term trend for Bioventus's free cash flow yield?
Over 3 years (2021 to 2025), Bioventus's free cash flow yield has grown at a 137.5% compound annual growth rate (CAGR), from 1.1% to 14.5%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.